Psychiatric medication induced obesity: An aetiologic review

Obesity Reviews

Volumn 5, Issue 3, 2004, Pages 167-170

  Virk, S ^a   Schwartz, T L ^a   Jindal, S ^a   Nihalani, N ^a   Jones, N ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Antidepressants; Antipsychotics; Obesity; Tolerability

Indexed keywords

ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CITALOPRAM; CLOZAPINE; FLUOXETINE; LITHIUM; NEUROLEPTIC AGENT; PAROXETINE; RISPERIDONE; SERTRALINE; THIORIDAZINE; TOPIRAMATE; TRANQUILIZER; VALPROIC ACID; ZIPRASIDONE;

BINDING AFFINITY; COMORBIDITY; DRUG RECEPTOR BINDING; GENETIC POLYMORPHISM; HUMAN; NEUROENDOCRINOLOGY; NEUROTRANSMISSION; NONHUMAN; OBESITY; PHARMACODYNAMICS; PHARMACOGENETICS; REVIEW; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; HUMANS; OBESITY;

EID: 3242875112     PISSN: 14677881     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1467-789X.2004.00141.x     Document Type: Review

References (39)

1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psych 1999; 156: 1686-1696.
2. Gothelf D, Falk B, Singer P, Kairi M, Phillip M, Zigel L, Poraz I, Frishman S, Constantini L, Zalsman G, Weizman A, Apter A. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psych 2002; 159: 1055-1057.
3. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psych 2001; 62(Suppl. 7): 22-31.
4. Kobayashi T, Ikeda K, Kumanishi T. Effects of clozapine on the delta- and kappa-opiod receptors and the G-protein activated K+ (GIRK) channel expressed in Xenopus oocytes. Br J Pharmacol 1998; 123: 421-426.
5. Curzon G, Gibson EL, Oluyomi AO. Appetite suppression by commonly used drugs depends on 5HT availability. Trends Pharmacol Sci 1998; 13: 12-25.
6. Strosberg AD, Pietri-Rouxel F. Function and regulation of beta-3 adrenoceptor. Trends Pharmacol Sci 1996; 17: 373-381.
7. Goodwin GM. How do antidepressants affect serotonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of the SSRI's. J Clin Psychiatry 1996; 57(Suppl. 4): 9-13.
8. Stahl SH. Essential Psychopharmacology. Cambridge University Press: New York, NY, 1996.
9. Brady K. Weight gain associated with psychotropic drugs. South Med J 1989; 82: 611-617.
10. Serger TS, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, Mclean S, Guanowsky V, Howard HR, Lowe JA III. Ziprasidone (CP 88.059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995; 275: 101-113.
11. Luef G, Abraham I, Haslinger M, Trinka E, Seppi K, Unterberger I, Alge A, Windisch J, Lechleitner M, Bauer G. Polycystic ovaries, obesity and insulin resistence in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women. J Neurol 2002; 249: 835-841.
12. Casey DE, Zorn SH. The pharmacology of weight gain with antipsychotics. J Clin Psych 2001; 62(Suppl. 7): 4-10.
13. Schmidt AW, Lebel LA, Johnson CG et al. The novel antipsychotic ziprasidone has a unique human receptor binding profile compared to other agents. Soc Neurosci Abstract 1998; 24: 2177.
14. Tandon R, Harrigan E, Zorn SH. Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutic potential. J Serotonin Res 1997; 4: 159-177.
15. Richelson E. Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry 1996; 57: 4-11.
16. Harvey BH, Bouver CD. Neuropharmacology of paradoxic weight gain with selective serotonin reuptake inhibitors. Clin Neuropharm 2000; 23: 90-97.
17. Bickerdike HJ, Vickers SP, Dourish CT. 5HT2c receptor modulation and the treatment of obesity. Diabetes Obes Metab 1999; 1: 207-214.
18. Sargent PA, Sharpey AL, Williams C, Goodall EM, Cowen PJ. 5HT2c receptor activation decreases appetite and body weight in obese subjects. Psychopharmacology 1997; 133: 309-312.
19. Sugimoto Y, Yamada J, Yoshikawa T, Noma T, Horisaka K. Effects of peripheral 5HT2c and 5HT3 receptor agonists on food intake in food deprived and 2-deoxy-17-glucose-treated rats. Em J Pharmacol 1996; 316: 15-21.
20. Currie PJ, Coscina DV. 5-Hydroxytryptaminergic receptor agonists: effects on neuropeptide Y potentiation of feeding and respiratory quotient. Brain Res 1998; 803: 212-217.
21. Sakata T, Yoshimatsa H, Kurokawa M. Hypothalamic neuronal histamine: implications of its homeostatic control of energy metabolism. Nutrition 1997; 13: 403-411.
22. Bouwer CD, Harvey BH. Phasic craving for carbohydrates observed with citalopram. Int Clin Psychopharmacol 1996; 11: 273-278.
23. Baptista T. Body weight gain induced by antipsychotic drugs: mechanism and management. Acta Psychiatr Scand 1999; 100: 3-16.
24. Vendsborg P, Bech P, Rafaelson O. Lithium treatment and weight gain. Acta Psychiatr Scand 1976; 53: 139-147.
25. Vendsberg P, Prytz S. Glucose tolerance and serum lipids in man after long term lithium administration. Acta Psychiatr Scand 1976; 53: 64-69.
26. Sussman N, Ginsberg D. Effect of psychotropic drugs on weight. Psychiatric Ann 1999; 29: 580-594.
27. Verrotti A, Basciani F, Morresi S, de Martino M, Morgese G, Chiarelli F. Serum leptin changes in epileptic patients who gain weight afterv therapy with valproic acid. Neurology 1999; 53: 230-232.
28. Baptista T, Reyes D, Hernandez L. Antipsychotic drugs and reproductive hormones: relationship to body weight regulation. Pharmacol Biochem Behav, 1999; 6: 409-417.
29. Demura R, Ono M, Demura H, Shizume K, Oouchi H. Prolactin directly inhibits basal as well as gonadotropin-stimulated secretion of progesterone and 17 beta-estradiol in the human ovary. J Clin Endocrinol Metab 1982; 54: 1246-1250.
30. Matsuzaki T, Azuma K, Irahara M, Yasui T, Aono T. Mechanisms of anovulation in hyperprolectinemic amenorrhea determined by pulsatile gonadotropin-releasing hormone injection combined with human chorionic gonadotropin. Fertil Steril 1994; 62: 1143-1149.
31. Dorrington J, Gore-Langton I. Prolactin inhibits estrogen synthesis in the ovary. Nature 1981; 290: 600-602.
32. Leibowitz SF, Hoebel BG. Behavioral Neuroscience of Obesity. In: Bray GA, Bouchard C, James WPT (eds). Handbook of Obesity Marcel Dekker: New York, 1998, pp. 313-358.
33. Breum L, Astrup A, Gram L, Andersen T, Stokholm KH, Christensen NJ, Werdelin L, Madsen J. Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. Metabolism 1992; 41: 666-670.
34. Schernthaner G, Prager R, Punzengruber C, Luger A. Severe hyperprolectinemia is associated with decreased insulin binding in vitro and insulin resistance in vitro. Diabetologia 1985; 28: 138-142.
35. Lambert PD, Wilding JP, Al-Dokhayel A, Bohuon C, Comoy E, Gilbey SG, Bloom SR. A role of neuropeptide Y, dynorphin and noradrenaline in the central control of food intake after food deprivation. Endocrinology 1993; 133: 29-32.
36. Stahl SM. Not so selective serotonin reuptake inhibitors. J Clin Psychiatry 1998; 59: 343-344.
37. Kraus T, Haack M, Schuld A. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999; 156: 312-314.
38. Rietschel M, naber D, Fimmers R, Moller HJ, Propping P, Nothen MM. Efficacy and side effects of clozapine not associated with variation in 5Ht2c receptor. Neuroreport 1997; 8: 1999-2003.
39. Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with 5-HT2c receptor gene polymorphism. Lancet 2002; 359: 2086-2087.